article · BMC Nephrology
Chronic kidney disease–mineral and bone disorder (CKD-MBD) contributes substantially to morbidity and reduced quality of life among patients receiving maintenance hemodialysis. Data regarding CKD-MBD burden and management in Ethiopia remain limited. This study assessed the prevalence of CKD-MBD biochemical abnormalities, adherence to KDIGO recommendations, CKD-MBD–related complications, and quality of life among maintenance hemodialysis patients in Addis Ababa, Ethiopia. We conducted an institution-based cross-sectional study among adult patients receiving maintenance hemodialysis at St Paul’s Hospital Millennium Medical College and affiliated private dialysis centers from 1 September 2025 to 28 February 2026. Sociodemographic, clinical, laboratory, treatment, and quality-of-life data were collected through structured interviews and medical record review. Multivariable logistic and linear regression analyses were performed to identify factors independently associated with CKD-MBD complications and lower quality of life. A total of 302 patients were included (response rate 89.1%). Elevated intact parathyroid hormone was observed in 47.4% of participants, hyperphosphatemia in 28.0%, hypocalcemia in 27.7%, and vitamin D deficiency in 19.6%. Adherence to KDIGO-recommended biochemical monitoring ranged from 53.6% to 62.9%. The most common CKD-MBD-related complications were bone pain and pruritus, both of which were independently associated with lower quality-of-life scores. Hyperphosphatemia, hypocalcemia, elevated iPTH, older age (≥60 years), and longer dialysis duration were independently associated with CKD-MBD complications. Older age, longer dialysis duration, hyperphosphatemia, hypocalcemia, and elevated iPTH were also independently associated with lower quality-of-life scores. CKD-MBD abnormalities and related complications are highly prevalent among maintenance hemodialysis patients in Ethiopia, with suboptimal adherence to KDIGO monitoring recommendations. Improved access to biochemical monitoring, guideline-concordant treatment, and multidisciplinary symptom management may help improve patient outcomes and quality of life.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1186/s12882-026-05272-7
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.